NCT00238329View on ClinicalTrials.gov

PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 31, 2001

Primary Completion Date

December 31, 2005

Study Completion Date

June 30, 2007

Conditions
Intraocular MelanomaMelanoma (Skin)
Interventions
BIOLOGICAL

PEG-interferon alfa-2b

DRUG

thalidomide

Trial Locations (1)

48201-1379

Barbara Ann Karmanos Cancer Institute, Detroit

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Barbara Ann Karmanos Cancer Institute

OTHER

NCT00238329 - PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma | Biotech Hunter | Biotech Hunter